PDK1 and neoplasm: To circumvent these limitations,a triphenylphosphonium (TPP) cation-modified nanoassembly (T-Mito-DCA-NP)was developed to achieve mitochondrion-targeted delivery of DCA, leadingto a reprogrammed immunosuppressive TMME (Table 2).77 T-Mito-DCA-NPwas shown to specifically inhibit PDK1 expression in the mitochondriaof tumor cells, thus reducing the rate of glycolysis and decreasingintratumoral lactate production.